Lupin names Christoph Funke as Chief Technical Operations Officer

Published On 2024-03-19 08:00 GMT   |   Update On 2024-03-19 08:00 GMT
Advertisement

Mumbai: Global pharma major Lupin Limited has announced the appointment of Christoph Funke to the newly-created position of Chief Technical Operations Officer. With over 30 years of global pharmaceutical manufacturing, supply chain, and technical operations experience, Christoph brings a wealth of expertise to Lupin. He will be based in Mumbai and will oversee Lupin's Technical Operations function, integrating manufacturing, supply chain, and procurement.

Christoph’s extensive career includes leadership roles at organizations such as Fresenius Kabi and Strides Pharma Science. In his leadership roles, Christoph has managed large-scale technical operations and manufacturing networks across 27 sites in 19 countries, overseeing production value exceeding USD 2 billion and leading teams of over 12,500 employees. Christoph holds an engineering degree from South Westphalia University of Applied Sciences, Germany.

Commenting on the appointment, Lupin’s CEO, Vinita Gupta, and MD, Nilesh Gupta said, “We are delighted to welcome Christoph to our executive leadership team. His impressive track record and extensive experience across manufacturing, supply chain, and technical operations make him a valuable addition as we continue to advance our mission of improving patient lives globally.”

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

The Company specializes in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women’s health areas. Lupin is the third-largest pharmaceutical company in the U.S. by prescriptions. The company invested 7.9% of its revenue in research and development in FY23. Lupin has 15 manufacturing sites, 7 research centers.

Read also: Lupin names Rakesh Bhardwaj as Chief Information Officer

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News